Sharon Wardlaw - Polydex Pharmaceuticals COO
| POLXFDelisted Stock | USD 1.96 0.01 0.51% |
COO
Ms. Sharon L. Wardlaw is Chief Operating Officer, Treasurer, Secretary of Polydex Pharmaceuticals Limited. She has served as the Chief Financial Officer, Secretary and Treasurer of the Company since 1994. In July 2006, she was appointed to the position of Chief Operating Officer. She also currently serves as the President of Dextran Products Limited, a subsidiary of the Company. Since joining the Company in 1984, she was employed in various capacities. since 2006.
| Age | 70 |
| Tenure | 19 years |
| Phone | 416 755 2231 |
| Web | https://www.polydex.com |
Polydex Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0824) % which means that it has lost $0.0824 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1802) %, meaning that it generated substantial loss on money invested by shareholders. Polydex Pharmaceuticals' management efficiency ratios could be used to measure how well Polydex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Polydex Pharmaceuticals has accumulated 301.49 K in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Polydex Pharmaceuticals has a current ratio of 5.76, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Polydex Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Polydex Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Polydex Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Polydex to invest in growth at high rates of return. When we think about Polydex Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | COO Age | ||
| Jeremy PEng | Senstar Technologies | 48 | |
Management Performance
| Return On Equity | -0.18 | |||
| Return On Asset | -0.0824 |
Polydex Pharmaceuticals Leadership Team
Elected by the shareholders, the Polydex Pharmaceuticals' board of directors comprises two types of representatives: Polydex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Polydex. The board's role is to monitor Polydex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Polydex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Polydex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sharon Wardlaw, COO, Secretary, Treasurer and Pres Dextran Products Limited | ||
| George Usher, Chairman, CEO and President and President of Chemdex Inc and VP of Dextran Products Limited |
Polydex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Polydex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Polydex Pink Sheet
If you are still planning to invest in Polydex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Polydex Pharmaceuticals' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |